HLB (028300) fell sharply amid strong selling pressure across the broader market, but managed to defend the psychologically important 30,000-won level. However, affiliates including HLB Pharmaceutical, HLB Life Sciences, and HLB Therapeutics also declined in tandem, signaling a significant contraction in investor sentiment.

As of the close of regular trading on the 20th, HLB finished at 30,550 won, down 4,750 won (13.46%) from the previous trading day. Despite widening losses during the session, the stock closed above the 30,000-won level.

On the same day, HLB group stocks also recorded declines across the board: • HLB Pharmaceutical: Down 1,310 won (13.98%) to 8,060 won • HLB Life Sciences: Down 275 won (11.55%) to 2,105 won • HLB Therapeutics: Down 142 won (7.66%) to 1,712 won

Investor sentiment across the broader domestic stock market also froze rapidly that day. The KOSDAQ index closed at 749.64, down 42.20 points (5.32%) from the previous trading day. In particular, a surge in program selling volume during the session triggered a 'selling sidecar,' significantly expanding market volatility.

The widened losses in HLB and its group stocks are attributed to the combination of a recent slowdown in investment sentiment toward risk assets and the sharp decline in the KOSDAQ.

Going forward, the key focal points for the stock's trajectory will be whether HLB can stably hold the current 30,000-won level and whether it can lay the groundwork for a rebound alongside its group stocks.

[※ This article is based on market trends and is not intended as a buy or sell recommendation or investment solicitation for any specific stock. Investment decisions and responsibilities lie with the investor.]